Gsa Capital Partners LLP Affimed N.V. Transaction History

Gsa Capital Partners LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.08 $58,429 - $110,708	102,508 Added 264.14%	141,316 $84,000
Q1 2023 May 12, 2023	BUY	$0.66 - $1.29 $25,613 - $50,062	38,808 New	38,808 $29,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $34,123 - $57,801	-17,410 Reduced 18.61%	76,164 $157,000
Q2 2022 Aug 09, 2022	BUY	$2.27 - $4.86 $25,417 - $54,417	11,197 Added 13.59%	93,574 $259,000
Q1 2022 May 11, 2022	SELL	$3.69 - $5.65 $707,465 - $1.08 Million	-191,725 Reduced 69.95%	82,377 $360,000
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $1.47 Million - $1.94 Million	274,102 New	274,102 $1.51 Million
Q2 2020 Aug 11, 2020	SELL	$1.58 - $4.63 $36,697 - $107,536	-23,226 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$1.44 - $3.02 $17,562 - $36,831	12,196 Added 110.57%	23,226 $37,000
Q4 2019 Feb 12, 2020	BUY	$2.25 - $3.07 $24,817 - $33,862	11,030 New	11,030 $30,000
Q3 2019 Nov 12, 2019	SELL	$2.67 - $3.65 $444,600 - $607,787	-166,517 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$2.6 - $4.21 $432,944 - $701,036	166,517 New	166,517 $478,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.